NeuroSense Therapeutics is a clinical-stage pharmaceutical company developing treatments for neurodegenerative diseases through novel combinations of established therapeutic agents. Its lead candidate, PrimeC, combines two FDA-approved drugs in a specific ratio to address unmet clinical needs, with additional programs in development targeting conditions such as Alzheimer's and Parkinson's disease. The company currently has no approved products or commercial revenues and funds its research and development operations through shareholder capital, directing all resources toward advancing its product candidates through clinical trials and regulatory pathways.
| USD millions | FY2025 |
|---|---|
| Net Income | -11 |